

Perimeter Medical Imaging AI

Investor Presentation – January 2024

TSXV: PINK | OTC: PYNKF | FSE: 4PC



Forward-Looking Statements

This presentation contains forward-looking statements. Words such as “may,” “would,” “could,” “will,” “likely,” “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management’s future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter.

Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; Perimeter’s expected marketing and sales activities; and the expected details regarding Perimeter’s ongoing clinical trials, including anticipated improvements in patient enrollment rates and the estimated completion date of enrollment, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management’s good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter’s control. Such forward-looking statements reflect Perimeter’s current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter’s financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter’s Management Discussion and Analysis for the year ended December 31, 2022, which is available on Perimeter’s SEDAR profile at www.sedar.com, and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

Indications for Use

The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest.

The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established.

For full information on unapproved/off-label uses, visit perimetermed.com/disclosures or contact medicalaffairs@perimetermed.com.

The Perimeter B-Series OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. Selene is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer.

Perimeter B-Series OCT is not available for sale in the United States. CAUTION - Investigational device. Limited by U.S. law to investigational use.



Perimeter – Driven to Transform Cancer Surgery


We envision a world where patients no longer experience the emotional and physical trauma of being called back for a second surgery due to cancer left behind.



Cancer's Far-Reaching Impact

4 in 10 lifetime risk¹

Cancer is a global challenge, impacting lives and families in countless ways.



Even for skilled surgeons, the odds of needing a repeat (re-excision) surgery due to positive margins are relatively high - nearly 1 in 4 for some types of cancer.

23%

of breast cancer lumpectomies
have a positive margin²

11.5%


of thyroid cancers have a
positive margin³

21%

of prostate cancers have a
positive margin³



It's All About Managing Margins




How does a surgeon know if they achieved clean margins?

Current Standard of Care



Perimeter Solution*



**OCT does not replace standard histopathology.*




Perimeter's Optical Coherence Tomography Platform Technology

AVAILABLE NOW




Perimeter S-Series OCT

- + Provides real-time insight on margin status
- + 10x the resolution of X-ray and ultrasound & 100x MRI



Perimeter OCT in the OR




Strongly Correlates to Post-Op Pathology




Potential Opportunities for Significant Market Expansion



Top 8 Cancers Represent ~\$1.2B Annually in U.S. Healthcare Costs Due to Re-Excisions



Approximate 5-Year Survival Rates



Large Economic Opportunity: Breast Cancer Surgery Use Case



~\$16K cost per re-excision

Includes annualized data for U.S. only

*Perimeter calculation for illustration purposes only



Surgeons Validate Clinical Fit

Beth Anglin, MD, FACS – Breast Surgeon, TX

“This technology can alleviate a surgeon’s uncertainty on margins and help address the possibility that they have to call a patient back for a second operation.



Michele Carpenter, MD, FACS – Breast Surgeon, CA

“With the Perimeter S-Series OCT*, I have a much better chance of getting clean margins the first time.



Amelia Tower, DO, FACOS – Breast Surgeon, TX

“As an early adopter of the S-Series OCT, I have seen its benefits firsthand and how it has positively impacted my patients.



Beth DuPree, MD, FACS, ABOIM – Breast Surgeon, PA

“I believe the next generation of Perimeter’s technology with AI is groundbreaking and could become the new standard of care for cancer surgery.



“Next-Gen” Development: B-Series* with AI



“This investigational and pioneering technology* allows surgeons to examine an excised tissue sample and identify areas of concern to support ‘real-time’ margin assessment during a surgery.

Alastair Thompson
Professor and Chief, Section of Breast Surgery,
Baylor College of Medicine



Participating Clinical Trial Sites



Baylor College of Medicine



WEST
CANCER CENTER
& RESEARCH INSTITUTE




Methodist
HEALTHCARE



WISCONSIN
UNIVERSITY OF WISCONSIN-MADISON



Go-to-Market Strategy



Leadership Team

Extensive experience and deep knowledge of AI and medical device technology space



Adrian Mendes
Chief Executive Officer

Experienced technology executive, investor and founder with 25 years of experience building and scaling technology companies across many different industries



Andrew Berkeley
Chief Innovation Officer

Company co-founder with over 20 years of experience in optical and medical imaging



Tom Boon
Chief Operating Officer

30+ years of experience in medical imaging



Sara Brien
Chief Financial Officer

Finance leader with over 20 years of across a variety of healthcare verticals



Dr. Sarah Butler
VP, Clinical & Medical Affairs

10 years of leadership and medical expertise in the development of clinical strategic programs



Carl Gazdzinski
VP, Engineering & Manufacturing

15 years in medical device engineering and development space



Adam Hodges
VP, Sales & Marketing

20+ years of commercialization experience in medical device industry

Board of Directors

Expertise and proven track record of success in clinical operations, medtech commercialization, and capital markets

Suzanne Foster, Chair



- President, Beckman Coulter Life Sciences part of the Danaher Corporation (NYSE: DHR)
- Former President at Cardinal (Home Health Division)
- Former GM of Medtronic (NYSE: MDT) (Transformative Solutions Division)

Aaron Davidson



- Former CFO and SVP Corporate Development of Profound Medical (TSX: PRN)
- Former Managing Director, H.I.G. Biohealth Partners where he led investments in several successful life sciences companies

Ian Mortimer



- President and CEO, Xenon Pharmaceuticals (NASDAQ:XENE)
- Former EVP & CFO, Tekmira Pharmaceuticals (NASDAQ:ABUS)
- Audit Committee Chair

Josh Vose, MD



- Experienced medical device executive with focus in breast oncology and reconstruction
- Former CEO and director at SIA Health through its acquisition by Integra LifeSciences (NASDAQ: IART)
- MBA from MIT Sloan School of Management and MD from Medical College of Georgia (focus on Surgery, Trauma, Critical Care)

Anantha Kancherla



- Engineering Director at Meta (Head of AI)
- Former VP, Engineering at Lyft
- Previous roles at Microsoft, Facebook and Dropbox

Hugh Cleland



- Co-founder and Principal at Roadmap Capital
- Founding Portfolio Manager at Northern Rivers Capital Management until acquisition by BluMont Capital in 2010
- Former roles at Midland Walwyn Capital and Interward Capital Corporation



Capital Structure

Ticker Symbol

TSXV: PINK | OTC: PYNKF | FSE: 4PC

Common Shares

64,675,739

Market Capitalization

~C\$105MM

Cash & Cash Equivalents

USD\$18.1 million*

Other Highlights

In Jan. 2022, Chamath Palihapitiya of Social Capital completes significant due diligence and becomes major shareholder of Perimeter through closing of C\$43.4 private placement, and subsequently appoints Anantha Kancherla (AI, Meta) to Board seat.

Analyst Coverage

Firm	Analyst
Leede Jones Gable	Douglas W. Loe
Paradigm Capital	Scott McAuley
Raymond James	Rahul Sarugaser



Perimeter Medical Imaging AI

TSXV: PINK | OTC: PYNKF | FSE: 4PC

For more information, contact: investors@perimetermed.com

